| Name | Title | Contact Details |
|---|
t+ Clinical is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Interactive Health, the country’s leading provider of health management solutions, creates innovative wellness programs designed to increase overall company health and actively engage employees to make lasting behavior changes. For every company’s perspective on health management, early stage or mature, Interactive Health has a highly flexible program to meet its needs. By offering health evaluations that detect risk proactively, Interactive Health has the capability to immediately intervene and engage at-risk participants with a personalized course of action. Using ActiveEngine(TM), a proprietary algorithmic-based clinical intelligence engine, a unique achievable goal is assigned to each participant based on individual results and health improvements are measured. Interactive Health has a 20+ year track record of creating the Healthiest Companies in America.
Accovion Inc. is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clay County Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Clay Center, KS. To find more information about Clay County Medical Center, please visit www.ccmcks.org
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.